Prognostic value of plasma neutrophil gelatinase-associated lipocalin for mortality in patients with heart failure

Circulation: Heart Failure

Volumn 7, Issue 1, 2014, Pages 35-42

  Van Deursen, Vincent M ^a   Damman, Kevin ^a   Voors, Adriaan A ^a   Van Der Wal, Martje H ^a   Jaarsma, Tiny ^b   Van Veldhuisen, Dirk J ^a   Hillege, Hans L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Heart failure; NGAL protein, human; Prognosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CALCIUM ANTAGONIST; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEW YORK HEART ASSOCIATION CLASS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; VERY ELDERLY;

HEART FAILURE; NGAL PROTEIN, HUMAN; PROGNOSIS;

ACUTE-PHASE PROTEINS; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COMORBIDITY; CYSTATIN C; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; LIPOCALINS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84895973360     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.113.000242     Document Type: Article

References (44)

1. Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TD, Cleland JG, van Veldhuisen DJ, Hillege HL. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail. 2007;13:599-608.
2. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ; Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671-678.
3. Damman K, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail. 2008;10:997-1000.
4. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006;17:17-25.
5. Nangaku M. Mechanisms of tubulointerstitial injury in the kidney: final common pathways to end-stage renal failure. Intern Med. 2004;43:9-17.
6. Eddy AA. Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol. 1994;5:1273-1287.
7. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis. 1992;20:1-17.
8. Zoja C, Benigni A, Remuzzi G. Cellular responses to protein overload: key event in renal disease progression. Curr Opin Nephrol Hypertens. 2004;13:31-37.
9. Fine LG, Bandyopadhay D, Norman JT. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int Suppl. 2000;75:S22-S26.
10. Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, Schreiner GF, Johnson RJ. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol. 2002;13:806-816.
11. Eckardt KU, Rosenberger C, Jürgensen JS, Wiesener MS. Role of hypoxia in the pathogenesis of renal disease. Blood Purif. 2003; 21:253-257.
12. Nangaku M. Hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. Nephron Exp Nephrol. 2004;98:e8-12.
13. Dupont M, Shrestha K, Singh D, Awad A, Kovach C, Scarcipino M, Maroo AP, Tang WH. Lack of significant renal tubular injury despite acute kidney injury in acute decompensated heart failure. Eur J Heart Fail. 2012;14:597-604.
14. Bolignano D, Coppolino G, Lacquaniti A, Buemi M. From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology. Eur J Clin Invest. 2010;40:273-276.
15. Ronco C. N-GAL: diagnosing AKI as soon as possible. Crit Care. 2007;11:173.
16. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;365:1231-1238.
17. Wagener G, Jan M, Kim M, Mori K, Barasch JM, Sladen RN, Lee HT. Association between increases in urinary neutrophil gelatinase- associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology. 2006;105:485-491.
18. Damman K, Van Veldhuisen DJ, Navis G, Vaidya VS, Smilde TD, Westenbrink BD, Bonventre JV, Voors AA, Hillege HL. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart. 2010;96:1297-1302.
19. Damman K, Masson S, Hillege HL, Maggioni AP, Voors AA, Opasich C, van Veldhuisen DJ, Montagna L, Cosmi F, Tognoni G, Tavazzi L, Latini R. Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J. 2011;32:2705-2712.
20. Bolignano D, Basile G, Parisi P, Coppolino G, Nicocia G, Buemi M. Increased plasma neutrophil gelatinase-associated lipocalin levels predict mortality in elderly patients with chronic heart failure. Rejuvenation Res. 2009;12:7-14.
21. Aghel A, Shrestha K, Mullens W, Borowski A, Tang WH. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail. 2010;16:49-54.
22. Alvelos M, Lourenço P, Dias C, Amorim M, Rema J, Leite AB, Guimarães JT, Almeida P, Bettencourt P. Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. Int J Cardiol. 2013;165:51-55.
23. Nymo SH, Ueland T, Askevold ET, Flo TH, Kjekshus J, Hulthe J, Wikstrand J, McMurray J, Van Veldhuisen DJ, Gullestad L, Aukrust P, Yndestad A. The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA. J Intern Med. 2012;271:436-443.
24. Maisel AS, Mueller C, Fitzgerald R, Brikhan R, Hiestand BC, Iqbal N, Clopton P, van Veldhuisen DJ. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail. 2011;13:846-851.
25. Jaarsma T, van der Wal MH, Lesman-Leegte I, Luttik ML, Hogenhuis J, Veeger NJ, Sanderman R, Hoes AW, van Gilst WH, Lok DJ, Dunselman PH, Tijssen JG, Hillege HL, van Veldhuisen DJ; Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH) Investigators. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med. 2008;168:316-324.
26. Jaarsma T, Van Der Wal MH, Hogenhuis J, Lesman I, Luttik ML, Veeger NJ, Van Veldhuisen DJ. Design and methodology of the COACH study: a multicenter randomised Coordinating study evaluating Outcomes of Advising and Counselling in Heart failure. Eur J Heart Fail. 2004;6:227-233.
27. Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation. 2006;114:1572-1580.
28. Postmus D, van Veldhuisen DJ, Jaarsma T, Luttik ML, Lassus J, Mebazaa A, Nieminen MS, Harjola VP, Lewsey J, Buskens E, Hillege HL. The COACH risk engine: a multistate model for predicting survival and hospitalization in patients with heart failure. Eur J Heart Fail. 2012;14:168-175.
29. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003;14:2534-2543.
30. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, Barasch J. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2007;18:407-413.
31. Ljungman S, Laragh JH, Cody RJ. Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs. 1990; 39(Suppl 4):10-21; discussion 22-24.
32. Packer M. Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. Eur Heart J. 1990;11(Suppl D):44-52.
33. Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int. 2008;73:1008-1016.
34. Herget-Rosenthal S, Marggraf G, Hüsing J, Göring F, Pietruck F, Janssen O, Philipp T, Kribben A. Early detection of acute renal failure by serum cystatin C. Kidney Int. 2004;66:1115-1122.
35. Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant. 2003;18:2024-2031.
36. Tan GD, Lewis AV, James TJ, Altmann P, Taylor RP, Levy JC. Clinical usefulness of cystatin C for the estimation of glomerular filtration rate in type 1 diabetes: reproducibility and accuracy compared with standard measures and iohexol clearance. Diabetes Care. 2002;25:2004-2009.
37. Kyhse-Andersen J, Schmidt C, Nordin G, Andersson B, Nilsson-Ehle P, Lindström V, Grubb A. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem. 1994;40:1921-1926.
38. Premaratne E, MacIsaac RJ, Finch S, Panagiotopoulos S, Ekinci E, Jerums G. Serial measurements of cystatin C are more accurate than creatinine-based methods in detecting declining renal function in type 1 diabetes. Diabetes Care. 2008;31:971-973.
39. Hsu CY, Chertow GM, Curhan GC. Methodological issues in studying the epidemiology of mild to moderate chronic renal insufficiency. Kidney Int. 2002;61:1567-1576.
40. Beddhu S, Samore MH, Roberts MS, Stoddard GJ, Pappas LM, Cheung AK. Creatinine production, nutrition, and glomerular filtration rate estimation. J Am Soc Nephrol. 2003;14:1000-1005.
41. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, Price CP. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int. 1995;47:312-318.
42. Keevil BG, Kilpatrick ES, Nichols SP, Maylor PW. Biological variation of cystatin C: implications for the assessment of glomerular filtration rate. Clin Chem. 1998;44:1535-1539.
43. Lee DS, Vasan RS. Novel markers for heart failure diagnosis and prognosis. Curr Opin Cardiol. 2005;20:201-210.
44. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008; 358:2148-2159.